The latest abstracts from Brigham and Women’s Hospital reveal the efficacy of Nanox.AI’s FDA-approved cardiac AI solution, showcasing strong concordance with expert evaluations. This technology has the potential to enhance guideline-directed preventive care, emphasizing its clinical value.